Activated cytotoxic T cells as prognostic marker in Hodgkin's disease

Blood

Volumn 89, Issue 4, 1997, Pages 1376-1382

  Oudejans, J J ^a   Jiwa, N M ^b   Kummer, J A ^b   Ossenkoppele, G J ^b   Van Heerde, P ^b   Baars, J W ^b   Kluin, Ph M ^b   Kluin Nelemans, J C ^b   Van Diest, P J ^b   Middeldorp, J M ^b   Meijer, C J L M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; GRANZYME A;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SURVIVAL TIME; SYMPTOMATOLOGY; TUMOR BIOPSY;

EID: 0031043575     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.4.1376     Document Type: Article

References (43)

1. Kadin ME: Hodgkin's disease: Immunobiology and pathogenesis, in Knowles DM (ed): Neoplastic Hematopathology. Baltimore, MD, Williams & Wilkins, 1992, p 535
2. Weiss LM, Movahed AM, Warnke RA, Sklar J: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320:502, 1989
3. Weiss LM, Strikter J, Warnke R, Purtilo DT, Sklar J: Epstein-Barr virus DNA in tissues of Hodgkin's disease. Am J Pathol 129:86, 1987
4. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H: Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern and in situ hybridization. Blood 74:810, 1989
5. Vasef MA, Kamel OW, Chen Y-Y, Medeiros LJ, Weiss LM: Detection of Epstein-Barr virus in multiple sites involved by Hodgkin's disease. Am J Pathol 147:1408, 1995
6. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Mueller-Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88:4766, 1991
7. Kadin ME: Pathology of Hodgkin's disease. Curr Opin Oncol 6:456, 1994
8. Drexler HG: Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma 8:283, 1992
9. Rosenberg SA: The treatment of Hodgkin's disease. Ann Oncol 5:17, 1995
10. Bonadonna G: Modern treatment of malignant lymphomas: A multi-disciplinary approach? Ann Oncol 5:5, 1994 (suppl 2)
11. Levy RA, Kaplan HS: Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med 290:181, 1974
12. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI: The impact of Hodgkin's disease on the immune system. Semin Oncol 17:673, 1990
13. Podack ER: Execution and suicide: Cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 7:11, 1995
14. Griffiths GM: The cell biology of CTL killing. Curr Opin Immunol 7:343, 1995
15. Shresta S, Maclvor DM, Heusel JW, Russel JH, Ley TJ: Natural killer and lymphokine activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. Proc Natl Acad Sci USA 92:5679, 1995
16. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogenic target cells. Cell 76:977, 1994
17. Kummer JA, Kamp AM, van Katwijk M, Brakenhoff JPJ, Radosevic K, van Leeuwen AM, Borst J, Verweij CL, Hack CE: Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods 163:77, 1993
18. Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJLM, Hack E: Localization and identification of granzymes A and B expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 100:164, 1995
19. Oudejans JJ, Jiwa NM, Kummer JA. Horstman A, Vos W, Baak JPA, Kluin PhM, van der Valk P, Walboomers JMM, Meijer CJLM: Analysis of MHC class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus positive and negative Hodgkin's disease. Blood 87:3844, 1996
20. Lukes RJ, Graver LF, Hall TC, Rappaport H, Ruben P: Report of the nomenclature committee. Cancer Res 26:1310, 1966
21. Jiwa NM, Kanavaros P, De Bruin PC, van der Valk P, Horstman A, Vos W, Mullink H, Walboomers JMM, Meijer CJLM: Presence of Epstein-Barr virus harbouring small and intermediate-sized cells in Hodgkin's disease. Is there a relationship with Reed-Sternberg cells? J Pathol 170:129, 1993
22. + T-lymphocytes. J lmmunol 144:574, 1990
23. Polkowski W, Meijer GA, Baak JPA, ten Kate FJW, Obertop H, Offerhaus JA, van Lanschot JJB: Reproducibility of p53 and Ki67 immunoquantification in Barrett's oesophagus. Anal Quant Cytol Histol (in press)
24. Fleege JC, van Diest PJ, Baak JPA: Computer assisted efficiency testing of different sampling methods for selective nuclear graphic tablet morphometry. Lab Invest 63:270, 1990
25. Cox DR: Regression models and life tables. J R Stat Soc Br 34:187, 1972
26. Medeiros LJ, Greiner TC: Hodgkin's disease. Cancer 75:357, 1995
27. Wedelin C, Bjorkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H: Prognostic factors in Hodgkin's disease with special reference to age. Cancer 53:1202, 1984
28. Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JM, Le Fur R, Somers R, Kluin-Nelemans JC, Busson A, Breed WP, Bron D, Holdrinet A, Rutten EHJM, Michiels JJ, Regnier R, Debusscher L, Musella R, Fargeut P, Thyss A, Cattan A, Rigal-Huguet F, Roth S, Caillou B, Dupony N, Henry-Amar M: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258, 1993
29. Vestlev PM, Pallesen G, Sandvej K, Hamilton-Dutoit SJ: Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent protein. Int J Cancer 50:670, 1992
30. Poppema S, Visser L: Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 145:37, 1994
31. Taga K, Tosato G: IL-IO inhibits human T-cell proliferation and IL-2 production. J lmmunol 148:1143, 1992
32. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R: Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371, 1994
33. Kerhl JH, Wakefield LM, Roberts AB, Jakowlev S, AlvarezMon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor-beta by human T-lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 163:1037. 1986
34. Rook AH, Kerhl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor B on the functions of natural killer cells. Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916, 1986
35. Newcom SR, Kadin ME, Ansari AA, Diehl V: L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest 83:1915, 1988
36. Ohshima K, Suzumiya J, Akamatu M, Takeshita M, Kikuchi M: Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes. Int J Cancer 62:5, 1995
37. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG: The Epstein-Barr virus latent membrane protein-1 (LMPl) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 57:240, 1994
38. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, Dere V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Ost O, Christensson B, Sundstrom C, Bjorkholm M, Pisa P. Masucci MG: Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493, 1995
39. Renner C, Ohnesorge S, Held G, Bauer S, Jung W. Pfitzenmeier J, Pfreundschuh M: T cells from patients with Hodgkin's disease have a defective T-cell receptor C chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88:236, 1996
40. Romeo C, Amiott M, Seed B: Sequence requirements for induction of cytolysis by the T-cell antigen Fc receptor C chain. Cell 69:889, 1992
41. Müller C, Tschopp J: Resistance of CTL to perforin-mediated lysis: Evidence for a lymphocyte membrane protein interacting with perform. J Immunol 153:2470, 1994
42. Oudejans JJ, Kummer JA, Jiwa NM, van der Valk P, Ossenkoppele GJ, Kluin PhM, Kluin-Nelemans JC, Meijer CJLM: Granzyme B expression in Reed Sternberg cells of Hodgkin's disease. Am J Pathol 148:233, 1996
43. Carbonne PP, Kaplan HS, Musschof K, Smithers DW: Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860, 1971